Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Zelira Therapeutics logo — Zelira Therapeutics (formerly Zelda Therapeutics) is a leadi...

Zelira Therapeutics

Zelira Therapeutics (formerly Zelda Therapeutics) is a leading global therapeutic medicinal cannabis company.

Founded 2015 Australia Australia 12 employees Post Ipo Equity Total: $13.20M Biotechnology, Health Care +2

General Information

Company Name Zelira Therapeutics
Founded Year 2015
Location Australia Australia +1
Employees 12
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Post Ipo Equity
Social

Get notified when Zelira Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Zelira Therapeutics

Zelira Therapeutics (formerly Zelda Therapeutics) is a leading global therapeutic medicinal cannabis company. Founded in 2003 and headquartered in Australia, the company operates in the biotechnology and health care industries, with access to the world’s largest and fastest-growing cannabis markets. Zelira Therapeutics recently secured a significant $8.60M Post-IPO Equity investment on 15 February 2023 from Cantheon Capital. With a focus on therapeutic medicinal cannabis, Zelira Therapeutics is positioned to capitalize on the increasing acceptance and legalization of medical cannabis globally. The company's strong presence in key markets, coupled with strategic investments, demonstrates its commitment to driving innovation and growth in the medicinal cannabis sector. As the medicinal cannabis industry continues to evolve and gain traction, Zelira Therapeutics appears well-positioned to leverage its expertise and expand its product offerings. The recent investment from Cantheon Capital not only provides the company with substantial capital but also signifies a vote of confidence in Zelira Therapeutics’ strategic vision and potential for long-term success. Zelira Therapeutics' ability to attract significant investment in the post-IPO phase reflects a positive outlook for the company and underscores its potential as a formidable player in the global medicinal cannabis market. With a solid foundation, access to key markets, and a robust investment from Cantheon Capital, Zelira Therapeutics looks poised for further expansion and impact in the therapeutic medicinal cannabis space. For more information, visit www.zeliratx.com.

Taxonomy: medicinal cannabis, therapeutic, global company, cannabis markets, pharmaceuticals, drug development

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $8.60M 1 Cantheon Capital 15 Feb 2023
Post-IPO Equity $4.60M - 05 Feb 2020

Zelira Therapeutics Alternatives & Competitors

Zelira Therapeutics vs
New Pill Technologies
New Pill Technologies

Pioneering AI-driven personalized cannabis therapeutics for superior self-care and real-time treatme...

Seed
Health Care
Zelira Therapeutics vs
IUVO Therapeutics
IUVO Therapeutics Germany

It's not for everyone.

11 employees
Zelira Therapeutics vs
Greenfern Industries
Greenfern Industries New Zealand

(NZX:GFI) Cannabis therapeutics | Patients before profit | Environmental sustainability | Hydropower

Equity Crowdfunding
6 employees
Health and Wellness
Also compare with: Zelira Therapeutics vs SOMAÍ SOMAÍ

FAQ About Zelira Therapeutics

Zelira Therapeutics (formerly Zelda Therapeutics) is a leading global therapeutic medicinal cannabis company.
Zelira Therapeutics was founded in 2015.
Zelira Therapeutics is headquartered in Australia.
Zelira Therapeutics operates in the following industries: Biotechnology, Health Care, Health and Wellness, Life Sciences.
Zelira Therapeutics has approximately 12 employees.
Zelira Therapeutics has completed 2 funding rounds, raising a total of $13.20M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Zelira Therapeutics include New Pill Technologies, IUVO Therapeutics, Greenfern Industries, Solstice Group, NUGL Media. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Zelira Therapeutics and New Pill Technologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Zelira Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy